News | December 14, 2024
Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio
The trademark rights for these brands will be transferred to Lupin by March next year.
The trademark rights for these brands will be transferred to Lupin by March next year.
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
US Generics grew 5% to Rs. 467 Crores for the quarter
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Subscribe To Our Newsletter & Stay Updated
